EQ - Equillium Inc logo

EQ

Equillium Inc

Rev โ€”top 1%5Y
Hold

Equillium, Inc. develops therapeutics to treat severe autoimmune and inflammatory disorders. Its pipeline includes EQ504 for ulcerative colitis and lung inflammation, and EQ302, an oral bi-specific inhibitor for celiac disease, targeting high unmet needs.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$358today

Score Overview

1 Year
Score
Net Growth-177.65%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-99.68%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth24.76%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend60%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-69.04%
Net Trend29%
Net Income Consistency
Rev Growthโ€”
Rev Trend43%
Revenue Consistency

See the full market ranking โ†’

Equillium Inc fundamental performance

Across Equillium Inc's full reported history, from 2018 to 2025, revenue grew from $ 0.00 to $ 130K and net income went from -$ 13M to -$ 22M. Revenue increased in 43% of the years measured; net income in 29%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.18โ€”
1 Year2025-08-12
$ 0.93133.38%
5 Years2021-08-12
$ 6.09-64.20%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 130K-$ 22M$ 30M
2024$ 41M-$ 8M$ 22M
2023$ 36M-$ 13M$ 40M
2022$ 15M-$ 62M$ 71M
2021$ 0.00-$ 38M$ 80M
2020$ 0.00-$ 29M$ 82M
2019$ 0.00-$ 25M$ 53M
IPO2018$ 0.00-$ 13M$ 65M

Explore beyond EQ

You're looking at Equillium Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies